SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Paul S. who wrote (829)5/25/1998 7:33:00 PM
From: Charles Salski  Respond to of 1185
 
Paul and All,
Re-reading the News Release >> F. Hoffmann-La Roche and Nortran Sign Agreement to Develop Drugs for Treatment of Atrial Arrhythmias <<

Under the terms of this agreement, Roche has paid Nortran a fee for the exclusive option to a worldwide (except for theASEAN nations) license to these compounds.
>>If Roche exercises its option, <<
Nortran will receive a license fee as well as milestone payments upon reaching certain stages of development and certain sales levels of a new drug. The maximum amount of such payments will be US $86.5 million. In addition, Roche will pay Nortran a royalty on sales of any product coming from the program.

Does anyone know when this maybe annouced?

Regards,
Charles



To: Paul S. who wrote (829)6/1/1998 9:45:00 PM
From: Wisee  Read Replies (1) | Respond to of 1185
 
To All,

The latest Mini-Cap Analyst dated May 31/98 has an excellent, detailed overview of Nortran & it's potential.

They think that a current price in the $3-$4 range is justifiable.

We have a HOME RUN here, but it's going to take some time.


Wisee


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News